Notably, although treatment with TRL had no effect on the inhibition of primary tumor formation in the pancreas (Fig. 5b), it significantly reduced the expression of COL17A1 and MMP2 (Fig. 5e, f). This evidence concerns the gene COL17A1 and neoplasm.